Myoinositol As a Safe and Alternative Approach in the Treatment of Infertile PCOS Women: A German Observational Study

Overview

Journal Int J Endocrinol

Publisher Wiley

Specialty Endocrinology

Date 2016 Sep 20

PMID 27642297

Citations 12

Authors

Pedro-Antonio Regidor

Adolf Eduard Schindler

Affiliations

Soon will be listed here.

Abstract

The use of 2 × 2000 mg myoinositol + 2 × 200 μg folic acid per day is a safe and promising tool in the effective improvement of symptoms and infertility for patients with a polycystic ovary syndrome (PCOS). Using a questionnaire an observational study was performed under German gynecologists to collect data on ovulation and pregnancy rates in PCOS patients with infertility. In this observational study, 3602 infertile women used myoinositol and folic acid between 2 and 3 months in a dosage of 2 × 2000 mg myoinositol + 2 × 200 μg folic acid per day. In a subgroup of 32 patients, hormonal values for testosterone, free testosterone, and progesterone were analyzed before and after 12 weeks of treatment. The mean time of use was 10.2 weeks. During this time 70% of these women had a restored ovulation, and 545 pregnancies were obtained. This means a pregnancy rate of 15.1% of all the myoinositol and folic acid users. In 19 cases a concomitant medication with clomiphene or dexamethasone was used. One twin pregnancy was documented. Testosterone levels changed from 96.6 ng/ml to 43.3 ng/ml and progesterone from 2.1 ng/ml to 12.3 ng/ml (p < 0.05) after 12 weeks of treatment. No relevant side effects were present among the patients. This study could show that a new treatment option for patients with a PCOS and infertility is available. The achieved pregnancy rates are at least in an equivalent or even superior range than those reported by the use of metformin.

Citing Articles

Inositols and female reproduction disorders: a consensus statement from the working group of the Club of the Italian Society of Endocrinology (SIE)-Women's Endocrinology.

Moretti C, Bonomi M, Dionese P, Federici S, Fulghesu A, Giannelli J J Endocrinol Invest. 2024; 47(9):2111-2141.

PMID: 39009925 DOI: 10.1007/s40618-024-02363-w.

Type and Frequency in Use of Nutraceutical and Micronutrient Supplementation for the Management of Polycystic Ovary Syndrome: A Systematic Scoping Review.

Scannell N, Mantzioris E, Rao V, Pandey C, Ee C, Mousa A Biomedicines. 2023; 11(12).

PMID: 38137570 PMC: 10742329. DOI: 10.3390/biomedicines11123349.

Application of multi-omic features clustering and pathway enrichment to clarify the impact of vitamin B2 supplementation on broiler caeca microbiome.

Mengucci C, Rampelli S, Picone G, Lucchi A, Litta G, Biagi E Front Microbiol. 2023; 14:1264361.

PMID: 37840729 PMC: 10568133. DOI: 10.3389/fmicb.2023.1264361.

Wide-genome selection of lactic acid bacteria harboring genes that promote the elimination of antinutritional factors.

Pham H, Kim D, Nguyen T Front Plant Sci. 2023; 14:1145041.

PMID: 37180381 PMC: 10171302. DOI: 10.3389/fpls.2023.1145041.

The "Asthma-Polycystic Ovary Overlap Syndrome" and the Therapeutic Role of Myo-Inositol.

Guarnieri G, Iervolino M, Cavallone S, Unfer V, Vianello A Int J Mol Sci. 2023; 24(8).

PMID: 37108123 PMC: 10138395. DOI: 10.3390/ijms24086959.

References

Rizzo P, Raffone E, Benedetto V . Effect of the treatment with myo-inositol plus folic acid plus melatonin in comparison with a treatment with myo-inositol plus folic acid on oocyte quality and pregnancy outcome in IVF cycles. A prospective, clinical trial. Eur Rev Med Pharmacol Sci. 2010; 14(6):555-61. View

Clements Jr R, Darnell B . Myo-inositol content of common foods: development of a high-myo-inositol diet. Am J Clin Nutr. 1980; 33(9):1954-67. DOI: 10.1093/ajcn/33.9.1954. View

Raffone E, Rizzo P, Benedetto V . Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women. Gynecol Endocrinol. 2010; 26(4):275-80. DOI: 10.3109/09513590903366996. View

Strugaru A, Botnariu G, Agoroaei L, Grigoriu I, Butnaru E . Metformin induced lactic acidosis--particularities and course. Rev Med Chir Soc Med Nat Iasi. 2014; 117(4):1035-42. View

Kamenov Z, Kolarov G, Gateva A, Carlomagno G, Genazzani A . Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance. Gynecol Endocrinol. 2014; 31(2):131-5. DOI: 10.3109/09513590.2014.964640. View

Sun T, Heimark D, Nguygen T, Nadler J, Larner J . Both myo-inositol to chiro-inositol epimerase activities and chiro-inositol to myo-inositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controls. Biochem Biophys Res Commun. 2002; 293(3):1092-8. DOI: 10.1016/S0006-291X(02)00313-3. View

Genazzani A, Prati A, Santagni S, Ricchieri F, Chierchia E, Rattighieri E . Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. Gynecol Endocrinol. 2012; 28(12):969-73. DOI: 10.3109/09513590.2012.685205. View

Hooper N . Glycosyl-phosphatidylinositol anchored membrane enzymes. Clin Chim Acta. 1998; 266(1):3-12. DOI: 10.1016/s0009-8981(97)00161-7. View

Morgante G, Orvieto R, Di Sabatino A, Musacchio M, De Leo V . The role of inositol supplementation in patients with polycystic ovary syndrome, with insulin resistance, undergoing the low-dose gonadotropin ovulation induction regimen. Fertil Steril. 2011; 95(8):2642-4. DOI: 10.1016/j.fertnstert.2011.01.035. View

10.

Carlomagno G, Unfer V . Inositol safety: clinical evidences. Eur Rev Med Pharmacol Sci. 2011; 15(8):931-6. View

11.

Unfer V, Carlomagno G, Dante G, Facchinetti F . Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol. 2012; 28(7):509-15. DOI: 10.3109/09513590.2011.650660. View

12.

Costantino D, Minozzi G, Minozzi E, Guaraldi C . Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur Rev Med Pharmacol Sci. 2009; 13(2):105-10. View

13.

Baillargeon J, Iuorno M, Nestler J . Insulin sensitizers for polycystic ovary syndrome. Clin Obstet Gynecol. 2003; 46(2):325-40. DOI: 10.1097/00003081-200306000-00011. View

14.

Gerli S, Papaleo E, Ferrari A, Di Renzo G . Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci. 2007; 11(5):347-54. View

15.

Genazzani A, Battaglia C, Malavasi B, Strucchi C, Tortolani F, Gamba O . Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertil Steril. 2004; 81(1):114-9. DOI: 10.1016/j.fertnstert.2003.05.020. View

16.

Kim C, Han K, Oh H, Tan K, Sothiratnam R, Tjokroprawiro A . Safety, tolerability, and efficacy of metformin extended-release oral antidiabetic therapy in patients with type 2 diabetes: an observational trial in Asia. J Diabetes. 2012; 4(4):395-406. PMC: 3549486. DOI: 10.1111/j.1753-0407.2012.00220.x. View

17.

Baillargeon J, Nestler J, Ostlund R, Apridonidze T, Diamanti-Kandarakis E . Greek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositols metabolism. Hum Reprod. 2008; 23(6):1439-46. PMC: 2729085. DOI: 10.1093/humrep/den097. View

18.

Legro R, Zaino R, Demers L, Kunselman A, Gnatuk C, Williams N . The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome. Am J Obstet Gynecol. 2007; 196(4):402.e1-10. DOI: 10.1016/j.ajog.2006.12.025. View

19.

Karimzadeh M, Javedani M . An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate-metformin in patients with polycystic ovary syndrome. Fertil Steril. 2009; 94(1):216-20. DOI: 10.1016/j.fertnstert.2009.02.078. View

20.

Croze M, Soulage C . Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie. 2013; 95(10):1811-27. DOI: 10.1016/j.biochi.2013.05.011. View